IVERIC bio, Inc. (ISEE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 14.82 |
| Open | 14.98 |
| Bid | 14.90 x 1200 |
| Ask | 17.15 x 1800 |
| Day's Range | 14.95 - 15.61 |
| 52 Week Range | 8.85 - 20.99 |
| Volume | |
| Avg. Volume | 5,516,561 |
| Market Cap | 1.831B |
| Beta (5Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.13 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.67 |
- Business Wire
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
PARSIPPANY, N.J., September 27, 2022--Iveric Bio will present top-line efficacy and safety results from GATHER2, the Company’s second Phase 3 clinical trial of Zimura, at AAO 2022.
- Motley Fool
Why Iveric Bio Stock Is Skyrocketing This Week
Investors are applauding the company's late-stage clinical results for its lead pipeline candidate.
- Zacks
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study
IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.
© 2022 Yahoo. All rights reserved.
